Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT03297606

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Led by Canadian Cancer Trials Group · Updated on 2026-03-27

720

Participants Needed

10

Research Sites

462 weeks

Total Duration

On this page

Sponsors

C

Canadian Cancer Trials Group

Lead Sponsor

A

AstraZeneca

Collaborating Sponsor

AI-Summary

What this Trial Is About

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

CONDITIONS

Official Title

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult (18 years or older) patient with a histologically-proven incurable metastatic solid tumor (excluding primary brain tumors), multiple myeloma, or B cell non-Hodgkin lymphoma (excluding CLL, SLL, and HCL).
  • No standard treatment known to prolong life or patient has refused such treatment.
  • ECOG performance status between 0 and 2.
  • Normal organ function including specified neutrophil counts, platelet levels, bilirubin, liver enzymes, and kidney function.
  • Patients must have measurable disease.
  • Results available from tumor genetic or protein testing showing a potentially actionable variant.
  • Patient consent obtained according to local and regulatory standards.
  • Patients accessible for treatment and follow-up at a participating center within reasonable geographic limits.
  • Women and men of childbearing potential agree to use highly effective contraception.
Not Eligible

You will not qualify if you...

  • Patients with prior or concurrent malignancy that could interfere with safety or study assessment.
  • Ongoing toxicity grade 2 or higher related to previous anti-tumor treatment, except certain corrected conditions and peripheral neuropathy below grade 3.
  • Receiving any other anti-cancer therapy except supportive care medications or ongoing castration therapy started at least one month prior.
  • Known active progressive brain metastases; previously treated brain metastases must be stable and without recent seizures.
  • Clinically significant cardiac conditions including uncontrolled angina, arrhythmias, or symptomatic heart failure.
  • Left ventricular ejection fraction below 40%.
  • Stroke or acute myocardial infarction within three months prior.
  • Acute gastrointestinal bleeding within one month prior.
  • Other significant medical conditions judged by the physician to interfere with study participation.
  • Lactating or nursing women.
  • Not meeting drug-specific eligibility for the chosen targeted therapy.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Cross Cancer Institute

Edmonton, Alberta, Canada, T6G 1Z2

Actively Recruiting

2

BCCA - Kelowna

Kelowna, British Columbia, Canada, V1Y 5L3

Actively Recruiting

3

BCCA - Vancouver

Vancouver, British Columbia, Canada, V5Z 4E6

Actively Recruiting

4

Kingston Health Sciences Centre

Kingston, Ontario, Canada, K7L 2V7

Actively Recruiting

5

London Health Sciences Centre Research Inc.

London, Ontario, Canada, N6A 5W9

Actively Recruiting

6

Ottawa Hospital Research Institute

Ottawa, Ontario, Canada, K1H 8L6

Actively Recruiting

7

University Health Network

Toronto, Ontario, Canada, M5G 2M9

Actively Recruiting

8

The Jewish General Hospital

Montreal, Quebec, Canada, H3T 1E2

Actively Recruiting

9

Allan Blair Cancer Centre

Regina, Saskatchewan, Canada, S4T 7T1

Actively Recruiting

10

Saskatoon Cancer Centre

Saskatoon, Saskatchewan, Canada, S7N 4H4

Actively Recruiting

Loading map...

Research Team

J

Janet Dancey

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

14

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here